Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Group 1: Acquisition and Corporate Strategy - Strive, Inc. has successfully completed the acquisition of Semler Scientific, making it the 11 largest public corporate holder of bitcoin globally with approximately 12,797.9 bitcoin [1] - The company aims to monetize the operating business from the Semler Scientific subsidiary by expanding its focus on early disease detection products under the leadership of newly appointed Chief Strategy Officer Avik Roy [2] Group 2: Leadership and Expertise - Avik Roy, who has a background in science from MIT and medical training from Yale, has extensive experience in biotech and healthcare, having worked at Bain Capital and J.P. Morgan [3] - Eric Semler, former chairman of Semler Scientific, has joined Strive as an independent board member, while Joe Burnett, previously director of Bitcoin Strategy for Semler Scientific, has taken on the role of VP of Bitcoin Strategy at Strive [4] Group 3: Company Overview - Strive is the first publicly traded asset management Bitcoin treasury company, focused on increasing Bitcoin per share to outperform Bitcoin over the long run, managing over $2 billion in assets since launching its first ETF in August 2022 [5] - Semler Scientific is recognized as a leader in medical devices and software for chronic diseases, with its flagship product QuantaFlo providing rapid point-of-care testing for peripheral arterial disease [6]

Key Takeaways HOLX launched the Ultimate Defense campaign in January to promote routine Pap HPV screening.Hologic highlights Pap HPV co-testing, which offers greater sensitivity than either test alone.HOLX is expanding Genius Digital Diagnostics, using FDA-cleared AI to ease lab shortages and screening.January is observed as Cervical Cancer Awareness Month, and Hologic (HOLX) has long been a leader in cervical cancer screening. The company developed the first FDA-approved liquid-based cytology test, the Thi ...

Core Insights - Ventripoint Diagnostics Ltd. has received approval from the TSX Venture Exchange to issue 1,164,044 common shares to satisfy $104,752 in interest payments on outstanding Convertible Debentures [1] - The Convertible Debentures carry an interest rate of 10% per annum, with interest payable every six months [1] - The shares will be issued at a deemed price of $0.09 and are subject to a hold period of four months and one day [1] Company Overview - Ventripoint is a leader in AI-enhanced cardiac imaging solutions, specifically in the application of AI to echocardiography [3] - The company's VMS+™ products utilize proprietary knowledge-based reconstruction technology, providing accurate volumetric cardiac measurements comparable to MRI [3] - Ventripoint's technology is an affordable alternative that enhances cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors [3]

Core Viewpoint - Vivos Therapeutics, Inc. has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $4.64 million in gross proceeds for the company [1][4]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices ranging from $3.83 to $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. - The offering is expected to close on or about January 20, 2026, subject to customary closing conditions [4]. Group 2: Company Overview - Vivos Therapeutics focuses on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [7]. - The company’s devices are FDA-cleared for treating OSA in both adults and children, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. - OSA affects over 1 billion people globally, with 90% undiagnosed, highlighting a significant market opportunity for Vivos [8]. Group 3: Strategic Intent - Vivos aims to empower healthcare providers to address the complex needs of OSA patients through innovative technology, education, and collaborations with sleep healthcare providers [9]. - The company promotes its treatment approach, known as The Vivos Method, which is a nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [10].

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Towards the end of October, I concluded that Boston Scientific ( BSX ) was continuing its M&A playbook, just as organic achievements were impressive. Supported by nearly 20% organic sales growth, ...

Core Insights - Profusa, Inc. has launched its Healthcare Research version of the Lumee tissue oxygen monitoring system targeting the global CRO market, which is projected to reach $47.9 billion by 2025, growing at a CAGR of 7% [1][3] - The initiative aims to meet the increasing demand for real-time biological data in drug development, allowing CRO partners to integrate the technology into their workflows with minimal implementation risk [2][4] Company Developments - Profusa's Lumee tissue oxygen products are commercially available and ready for immediate deployment, providing continuous, real-time measurement of tissue oxygenation for various research applications [4] - The company has appointed Sean Givens as the Head of Government and Healthcare Research Business to lead commercialization efforts, emphasizing the strong interest in their validated sensors across the industry [5][6] Market Context - The CRO and pharmaceutical services market is experiencing robust growth due to rising R&D investments and regulatory support for new methodologies, with forecasts indicating the market could expand to over $91.2 billion by 2034 [3] - Profusa's technology supports research into complex biological processes, enhancing the ability to gather biologically relevant data beyond traditional endpoint assays [4]

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) today announced that it has entered into a 90-day lock-up agreement with SOL Markets (the “Strategic Advisor”), pursuant to which SOL Markets has agreed to restrict sales of its advisory warrants and any underlying shares. The lock-up reflects strong conviction in STSS’s execution roadmap and reinforces alignment between the parties. This comes after the company's recent announcement that its Board of Directors approved a sha ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: STAAR Surgical’s CEO is stepping down after the implantable eye lens manufacturer opposed a $1.6 billion takeover. Encouraged by activist investor Broadwood Partners, STAAR shareholders rejected Alcon’s $1.6 billion offer last week. Thursday, STAAR revealed a cooperation agreement with Broadwood that has reshaped its board. Stephen Farrell has left th ...

Core Insights - The "FDA Recalls Masterclass" training aims to enhance recall management strategies and compliance with FDA regulations [1] - The course emphasizes the importance of identifying root causes of recalls and implementing corrective and preventive action programs to avoid future issues [2] - Effective recall management is crucial for maintaining a company's reputation and minimizing financial losses associated with recalls [3] Training Overview - The training will cover essential aspects of FDA recalls, including definitions, types (Class I, II, III), and the FDA's recall authority and policy [8] - Participants will learn how to manage recalls under FDA oversight, interact with FDA staff, and develop health risk determinations [9] - The agenda includes sessions on proactive recall readiness, risk-based planning, executing recalls, and post-recall actions [10] Target Audience - The training is designed for recall managers, quality assurance managers, regulatory affairs directors, risk and product liability managers, and manufacturers [9] - It is also relevant for healthcare institutions, nursing homes, and medical practice groups [9] Key Topics - The course will address building compliant recall plans, setting up cross-functional recall teams, and conducting mock recall exercises [11] - It will cover notification procedures, managing media communications, and ensuring compliance through effectiveness checks [11] - Participants will engage in discussions on common pitfalls and best practices in recall management [11]